Analyst Ratings For Regeneron Pharmaceuticals (NASDAQ:REGN)
Today, Regeneron Pharmaceuticals (NASDAQ:REGN) stock was downgraded by Robert W. Baird from Neutral to Underperform with a price target of $408.00.
There are 1 sell rating, 14 hold ratings, 11 buy ratings on the stock.
The current consensus rating on Regeneron Pharmaceuticals (NASDAQ:REGN) is Hold (Score: 2.38) with a consensus target price of $476.30 per share, a potential 3.12% downside.
Some recent analyst ratings include
- 8/1/2017-Robert W. Baird was Downgraded by analysts at Robert W. Baird from a “Neutral ” rating to a ” Underperform” rating. They now have a $408.00 price target on the stock.
- 7/31/2017-BMO Capital Markets Reiterated Rating of Market Perform.
- 7/22/2017-Barclays PLC Reiterated Rating of Equal Weight.
- 7/21/2017-Bank of America Corporation Reiterated Rating of Buy.
- 7/14/2017-Credit Suisse Group was Downgraded by analysts at Credit Suisse Group from a “Hold” rating to a “” rating. They now have a $485.00 price target on the stock.
- 7/10/2017-Morgan Stanley Reiterated Rating of Equal Weight.
Recent Insider Trading Activity For Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) has insider ownership of 10.40% and institutional ownership of 66.79%.
- On 6/22/2017 Michael S Aberman, SVP, sold 2,269 with an average share price of $532.42 per share and the total transaction amounting to $1,208,060.98. View SEC Filing
- On 6/22/2017 Neil Stahl, EVP, sold 8,306 with an average share price of $532.55 per share and the total transaction amounting to $4,423,360.30. View SEC Filing
- On 6/20/2017 Michael S Brown, Director, sold 3,000 with an average share price of $500.00 per share and the total transaction amounting to $1,500,000.00. View SEC Filing
- On 6/16/2017 Robert J Terifay, EVP, sold 21,147 with an average share price of $468.19 per share and the total transaction amounting to $9,900,813.93. View SEC Filing
- On 6/15/2017 Neil Stahl, EVP, sold 8,567 with an average share price of $468.45 per share and the total transaction amounting to $4,013,211.15. View SEC Filing
- On 6/9/2017 Joseph L Goldstein, Director, sold 1,000 with an average share price of $482.55 per share and the total transaction amounting to $482,550.00. View SEC Filing
- On 6/2/2017 Neil Stahl, EVP, sold 2,812 with an average share price of $479.49 per share and the total transaction amounting to $1,348,325.88. View SEC Filing
Recent Trading Activity for Regeneron Pharmaceuticals (NASDAQ:REGN)
Shares of Regeneron Pharmaceuticals closed the previous trading session at 491.62 down -17.09 -3.36% with 1,008,967 shares trading hands.
